TrialLancet (London, England)2024

Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.

Seung-Jung Park et al.PubMed ↗Publisher ↗

No numbers read from the abstract.